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Plasmodium falciparum signal recognition particle
components and anti-parasitic effect of ivermectin
in blocking nucleo-cytoplasmic shuttling of SRP
M Panchal1,2, K Rawat1,2, G Kumar1, KM Kibria1, S Singh1, Md Kalamuddin1, A Mohmmed1, P Malhotra*,1 and R Tuteja*,1
Signal recognition particle (SRP) is a ubiquitous ribonucleoprotein complex that targets proteins to endoplasmic reticulum (ER)
in eukaryotes. Here we report that Plasmodium falciparum SRP is composed of six polypeptides; SRP9, SRP14, SRP19, SRP54,
SRP68 and SRP72 and a 303nt long SRP RNA. We generated four transgenic parasite lines expressing SRP-GFP chimeric
proteins and co-localization studies showed the nucleo-cytoplasmic localization for these proteins. The evaluation of the effect
of known SRP and nuclear import/export inhibitors on P. falciparum revealed that ivermectin, an inhibitor of importin a/b
mediated nuclear import inhibited the nuclear import of PfSRP polypeptides at submicromolar concentration, thereby killing the
parasites. These findings provide insights into dynamic structure of P. falciparum SRP and also raise the possibility that
ivermectin could be used in combination with other antimalarial agents to control the disease.
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The protein targeting in Plasmodium falciparum is a complex
process that involves an extensive network of rough endo-
plasmic reticulum (ER), an unstacked Golgi situated anterior
to the nucleus along with characteristic apicocomplexan
organelles—rhoptries, micronemes and dense granules.1–4
The biogenesis of the secretory organelles, their relationship
to the organelles of higher eukaryotes and various sorting
events that allow the proteins to get targeted to the right place
are poorly understood in P. falciparum. The signal recognition
particle (SRP), a cytoplasmic ribonucleoprotein complex,
coordinates the targeting of nascent secretory as well as
membrane proteins to the translocation machinery of the
cells.5,6 In addition to the targeting function, SRP also does
the elongation arrest or pausing function.7 SRPs have been
identified from all the three kingdoms based on their
phylogenetically conserved sequences and their structures.8
The eukaryotic SRP is composed of a B300 nucleotide 7S
RNA to which six distinct polypeptides; SRP9, 14, 19, 54, 68
and 72 are attached.8,9 SRPs of bacteria are far simpler than
its eukaryotic counterpart. In Eschericha coli, SRP consists of
a 4.5S RNA to which a single polypeptide, the SRP54
homologue Ffh is attached. SRPs of Leishmania major,
Giardia lambia and Trypanosoma brucei contain SRP19, 54,
68 and 72 homologues but do not possess SRP9/14
homologues.10,11 The molecular and structural studies in
mammalian cells have shown that SRP polypeptides; SRP-9,
-14, -19, -68 and -72 are imported into the nucleus where they
bind SRP RNA.12 The partially assembled SRP is exported
out of nucleus in the cytoplasm and is joined by SRP54. The
assembled SRP thereafter recognizes the under synthesized
polypeptide resulting in elongation arrest.7 It has been shown
that the binding of SRP19 to 7S RNA introduces some
conformational changes in the RNA molecule, which enables
SRP54 to bind it.13,14 SRP54 acts as a front runner protein in
recognizing the signal sequence flaunted by newly synthe-
sized polypeptide chain of translating ribosome. The phenom-
enon of elongation arrest is considered to be essential, as the
cell has to keep pace with the limited number of SRP receptors
available on the membrane. The elongation resumes only
when the whole conglomeration is transferred to the Sec62
translocon. The importance of components of this protein
translocation machinery has been well documented in
humans, where mutations in the components of transport
machinery have been shown to cause various human
diseases, thereby suggesting that this is an important and
vital pathway.15
In P. falciparum, although a number of studies have
reported the identification of few major components of protein
translocation pathway by in silico analysis using Plasmodb
data base,16–18 however, till now Plasmodium protein
translocation machinery has not been characterized. In the
present study, we identified seven P. falciparum SRP
constituents and characterized them biochemically as well
as for their sub-cellular distribution at asexual blood stages by
generating SRP-GFP transgenic parasite lines. We further
investigated the effects of exportin/importin and SRP
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assembly inhibitors on parasite growth in vitro and studied in
detail the mode of action of ivermectin. Our results provide
new insights into the molecular organization of P. falciparum
SRP and set the stage to further analyze the antimalarial
effect of ivermectin clinically.
Results
Identification of P. falciparum SRP components,
characterization of PfSRP RNA and PfSRP 9, 14, 19,
and 54. The domain specific search of the recent
P. falciparum data base using the amino acid sequences of
the human SRP proteins and SRP RNA was performed.
The query identified all the predicted human SRP
homologues in P. falciparum genome with PlasmoDB
numbers PF3D7_0729000 (PfSRP9), PF3D7_1203200
(PfSRP14), PF3D7_1216300 (PfSRP19), PF3D7_1450100
(PfSRP54), PF3D7_0621900 (PfSRP68), PF3D7_1136400
(PfSRP72) and (PfSRP RNA) (Figures 1a and b). PfSRP72
as well as PfSRP68 homologs were identified based on
protein–protein and protein–RNA interaction motifs. The
annotated PfSRP68 sequence possesses a conserved
SRP72 interacting domain, FSPKMKEISLNPLHIDMTQ
MYRSTSY of the form FSPKMKEISLNPLHIDMTQMYR
[TSYL] located at amino acid positions 728–753 in
P. falciparum, which harbours the conserved aspartic acid
shown to be important for binding of human SRP68 protein.19
PfSRP72 possesses a conserved 7SL RNA binding domain,
PDPERWLPLRD of the form PDRWLPKHEK located at
amino acid positions 832–840 in P. falciparum. PfSRP72
also possesses the conserved tetrapeptide repeat motif
(TPR) consisting of Y110, Q145 and Y153 which has been
suggested to mediate interaction with SRP68 (Figure 1b).
Together these results suggest that P. falciparum SRP is
composed of aB300 nt RNA and six polypeptides with
masses 12.1, 11.8, 18, 55.9, 92.5 and 107.1 kDa. The
coding sequences of predicted PfSRP54, PfSRP19,
PfSRP14, PfSRP9 and PfSRP RNA were PCR amplified,
cloned and sequenced. The sequence analysis of the PCR
products showed no differences from the sequences in
PlasmoDB data base.
Expression and purification of recombinant PfSRP 9, 14,
19 and 54. To functionally characterize PfSRP polypeptide
homologues, these genes were sub-cloned in E. coli
expression vectors pET28a or pET28b. A moderate level of
expression was seen for the four recombinant PfSRP
proteins. The recombinant proteins were subsequently
purified on a Ni-NTAþ column under non-denaturing condi-
tions. The apparent molecular masses of the recombinant
proteins PfSRP19, PfSRP14 and PfSRP9 areB19,B14 and
B12 kDa respectively (Supplementary Figures S1b–d). In
the case of PfSRP54, two additional bands of lower
molecular weight were always seen along with the intact
protein after purification and all three bands were recognized
on a western blot by anti-His antibody, thereby suggesting
that these two additional bands were the degradation product
of the intact protein (Supplementary Figure S1a, iii). The
purified recombinant PfSRP54 was unstable as no intact
protein was detected after storage. Therefore, to
characterize PfSRP54, two distinct domains covering the
entire sequence of PfSRP54; a GTP binding domain (NG
domain) and a methionine rich domain (M domain) were
cloned in pET28a and expressed. Both the PfSRP54
domains; PfSRP-54NG and PfSRP-54M were purified on a
Ni-NTAþ column up to near homogeneity (Supplementary
Figures S1a, i and ii). The purified recombinant PfSRP
proteins were used to raise antibodies in mice and rats.
Immunoblot analysis of P. falciparum 3D7 parasite lysate
using anti-PfSRP54, -PfSRP19, -PfSRP14 and -PfSRP9
antibodies recognized their respective native proteins of
B54, B19, B12, and B12 kDa corresponding to the actual
size of the native proteins. Pre-immune sera failed to detect
any band in P. falciparum lysate (Figures 1c, i-v). The
specificity of the antibodies was further confirmed by
immunolocalization study at asexual blood stages of the
parasite. P. falciparum SRP polypeptides are expressed in all
three blood stages; ring, trophozoite and schizont (Figures 1d
(i-iv) and Supplementary Figures S1e, i-iv). The staining was
seen in the parasite cytoplasm and to some extent in the
nucleus as well. No staining was observed in parasites with
preimmune sera.
PfSRP polypeptides show bi-compartmental (nucleo-
cytoplasmic) localization. To decipher the sub-cellular
localization of P. falciparum SRP polypeptides, four transgenic
parasite lines expressing PfSRP54, PfSRP19, PfSRP14 and
PfSRP9 as chimeric proteins with GFP were generated.
Figures 2a–d, upper panels show the schematic of the
PfSRP54-GFP, PfSRP19-GFP, PfSRP14-GFP and PfSRP9-
GFP fusion constructs used for transfecting the parasite. The
localizations of PfSRPs-GFP by fluorescence microscopy of
live parasites were also investigated. At the early stage of
development 420 h (ring stage), a crescent shaped staining
was observed that changed into a ring of fluorescence
around the nuclear envelop at the trophozoite stage (Figures
2a–d, lower panels i and ii). In later stages, staining was quite
intense and spread through-out the cytoplasm (Figures 2a–d,
lower panel iii). At schizont stage, extensive ER branching
creating a mesh-like network in some sections was observed
(Figures 2a–d, lower panel iii). The PfSRP54 staining was
mainly observed in cytosol (Figure 2a, lower panels). In
comparison to PfSRP54 distribution in the nucleus, staining
for PfSRP19, PfSRP14 and PfSRP9 in subnuclear areas
was quite intense at the asexual blood stages particularly
at the trophozoite stage (Figures 2b–d, lower panel ii,
Supplementary Figure S2). The inspection of transgenic
parasites by confocal microscopy (mid-depth Z slice) also
revealed the nucleo-cytoplasmic distribution of PfSRP-
chimeric proteins (Figures 2c and d, lower panel iv). To
further confirm the bi-compartmental localization of PfSRP
polypeptides, co-localization experiments for the parasite SRP
polypeptides with PfNOP1, a known nucleolar marker20 or
with PfBiP, an ER marker21 were performed with their
respective antibodies. A considerable overlap in staining was
observed between three PfSRP polypeptides; PfSRP19, -14,
and -9 with PfNOP1 and with PfBiP protein (Figures 3a and b,
i-iv). Importantly, considerable co-localization of PfSRP54 with
PfNOP1 in early stages of parasite development i.e. merozoite
and ring stages (Figure 3a, i and Supplementary Figure S3)
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Figure 1 Schematic representation of domain architecture and expression of PfSRP polypeptides. (a) conserved domains of PfSRP54, PfSRP19, PfSRP14 and PfSRP9
predicted by CDART (http://www.ncbi.nlm.nih.gov/cdd). (b) Aligned representation of conserved domains of PfSRP72 and PfSRP68. Regions marked in yellow show
conserved sequences. (c, i-iv) Western blot of expression of PfSRP54, PfSRP19, PfSRP14 and PfSRP9 in P. falciparum as detected by specific anti-PfSRP54, anti-PfSRP19
and anti-PfSRP14 and PfSRP9 sera in the parasite lysate. (c v) Western blot with mice pre-immune sera (d) Immuno-fluorescence staining of PfSRP54, PfSRP19, PfSRP14
and PfSRP9 in P. falciparum detected by specific anti-PfSRP54, anti-PfSRP19 and anti-PfSRP14 and PfSRP9 sera
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Figure 2 Localisation of GFP fused PfSRP54, PfSRP19, PfSRP14 and PfSRP9 polypeptides. Upper panels of a, b, c and d show schematic representation of respective
GFP fused PfSRP polypeptides. Lower panels show the expression of PfSRP polypeptides in three asexual blood stages of P. falciparum i.e. ring, trophozoite and schizont
stage. Panel c(iv) and d(iv) show three dimensional reconstruction of confocal Z-stack merged images of GFP fused PfSRP19 and PfSRP14 (green), respectively, along with
nuclear stain DAPI (blue)
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was observed. In addition considerable co-localization
between the GFP protein and the cytoplasmic marker
Pfactin, along with ER tracker (invitrogen) was also
observed (Figures 3c and d). These results collectively
suggest that the parasite’s SRPs reside in nucleus and ER
membrane.
PfSRP assembly involves protein–RNA and protein–
protein interactions. In vitro binding studies in mammalian
cells have revealed that SRP RNA is at the centre of
structure of SRP complex.9 Protein–RNA interaction by an
RNA binding assay and protein–protein interactions by
bacterial two hybrid analysis were performed with PfSRP
RNA and between PfSRP proteins to understand the
assembly of P. falciparum signal recognition particle.
The results of protein/RNA interaction studies showed that
PfSRP19 bound to the S domain of PfSRP RNA (Figure 4a) as
well as to the full length SRP RNA (Figure 4b, lane E1).
Similarly, PfSRP54 also bound the S domain and intact PfSRP
RNA similar to PfSRP19 protein (Figure 4b, lanes E2 and E4).
Moreover, PfSRP-9, -14, -19 and -54 together bound strongly
to the intact full length PfSRP RNA (Figure 4b, lane E5).
However, PfSRP RNA was unable to bind to a non-SRP
protein, PfHDP (25 kDa) (Figure 4b, lane E3). These results
support identification of PfSRP genes in the present study as
the real constituents of the P. falciparum SRP machinery and
further suggest that PfSRP RNA like its other homologs
provides a backbone for the coordinated assembly of
PfSRP proteins.
To know whether PfSRP assembly also involves protein–
protein interactions besides protein–RNA interactions,
direct interaction studies between PfSRP54, -19, -14 and -9
using an ELISA based approach or by a well established
bacterial two-hybrid interaction approach were performed.
PfSRP54 PfSRP19 PfSRP14 PfSRP9
Pf
NO
P1
Pf
Bi
P
PfSRP19 + DAPI ACTIN + DAPI ALL MERGE
PfSRP19 + DAPI ER Tracker + DAPI ALL MERGE
Z-section
Z-section
Figure 3 Co-staining of PfSRP polypeptides with nucleolar marker PfNOP1, ER marker PfBiP and cytoplasmic marker Pfactin. (a, b and c) P. falciparum infected
erythrocytes stained with anti-PfSRP antibodies (green), anti-PfNOP1 (red), anti-PfBiP (red) and anti-Pfactin (red) respectively. (d) localization of GFP fused SRP19 (green)
with ER tracker (red). DAPI is used for nuclear staining (blue)
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Varying degrees of interactions among the four SRP
polypeptides were observed but no interaction between
PfSRP19 and PfSRP54 was seen (Figures 4c–e and
Supplementary Figure S4). The associations between these
PfSRP proteins in vivo were also illustrated by the
co-localization studies performed at asexual blood
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Figure 4 Interaction between PfSRP polypeptides and SRPRNA. (a) schematic diagram of secondary structure of PfSRP RNA showing the Alu domain and S domain (b).
Binding of SRP RNA to SRP 19 and M domain of SRP 54. FT represents the lanes with flow through. Elutes of S domain of SRP RNA binding (by DEAE sepharose method)
showing the presence of SRP19 (E1), SRP19 and M-domain of SRP54( E2). Elutes of full SRP RNA binding (by DEAE sepharose method) with non-SRP protein PfHDP (E3)
and PfSRP19 and SRP54 (E4), and all four PfSRP54 (M-domain), PfSRP19, PfSRP14, PfSRP9 (E5). (c) Interaction between protein components of PfSRP polypeptides
using Bacterial Two Hybrid system. Growth of cotransformed reporter strain XL1-blue in dual selective (i) and non-selective (ii) medium, (iii) shows the plasmid constructs used
to cotransform the reporter strain. (d) Interaction between protein components of PfSRP polypeptides using ELISA. X-axis shows the coated protein and Y-axis is absorbance
read at 490 nm. (e) Table showing summary of interactions among all PfSRP polypeptides using both ELISA and Bacterial Two Hybrid system
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stages of the parasite using their respective antibodies
(Supplementary Figure S2).
Effect of aflatoxin B1, leptomycin B and ivermectin on
PfSRP distribution and parasite growth. A number of
inhibitors/drugs such as aflatoxin B1 (AFB1), leptomycin B
(LMB) and ivermectin have been shown to either interact with
SRP components or inhibit protein nuclear export/import
machinery.22–24 We tested the effect of these inhibitors on
transgenic parasite lines. AFB1 up to 5 mM and LMB up to
100 ng/ml had no significant effect on PfSRP9-GFP protein
distribution and on parasite growth (Figures 5a and b and
Supplementary Figures S5a and b). Ivermectin, an inhibitor
of importin a/b, at 10 mM to 25 mM showed pronounced
effects 24 h after the treatment on PfSRP9-GFP transgenic
parasites (Figure 5c). The distribution of GFP-fused PfSRP9
chimeric protein was concentrated in parasite cytoplasm in
the treated parasites, in comparison to the untreated parasite
culture where the chimeric protein showed the nucleo-
cytoplasmic distribution. The effect was more pronounced
at 25mM concentration of ivermectin (Figure 5c). The
removal of ivermectin from the culture media after 24 h did
not alter the growth of the parasite i.e. effect of the drug was
irreversible. A similar block in nucleo-cytoplasmic shuttling
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Figure 5 Effect of aflatoxin B1, leptomycin B and ivermectin, on nucleo-cytoplasmic shuttling of GFP fused PfSRP9. Synchronised ring stage infected erythrocytes at 2%
initial parasitemia were treated with these inhibitors and imaged at different time intervals. (a) upper panel, DMSO treated control parasite after 24 h of treatment, lower panel,
AflatoxinB1 (AFB1, 10mM ) treated parasite at 24 h after treatment. (b) LeptomycinB (LMB, 25 ng/ml ) treated parasite at 24 h after treatment and (c) parasite after 24 h of
ivermectin (IVM) treatment at10mM and 25mM, respectively
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was observed for GFP fused PfSRP14 transgenic parasites
(Figures 6b and c and supplementary videos 1 and 2).
Subsequently, the effect of ivermectin on parasite growth
was assessed by the SYBR green based assay on different
P. falciparum drug resistant strains; chloroquine (CQ)/
mefloquine resistant (DD2 and MCamp) along with a
chloroquine sensitive strain P. falciparum 3D7. Ivermectin
exhibited anti-plasmodial activity against all the three
20
 h
20
 h
Trophozoite
(PfSRP14)
i ii
Iv
er
m
ec
tin
 (1
0
M
)
N
o 
Iv
er
m
ec
tin
Arrested trophozoiteSchizont
100
80
100 3D7
MCAMP
60
Dd2
50
40
Pe
rc
en
ta
ge
 o
f g
ro
w
th
0
Pe
rc
en
t s
ur
vi
va
l
0
20
Ivermectin (M) days
0 10 20 300
2 m
2 m 2 m
5 10 15 20
Figure 6 Effect of Ivermectin on localisation of GFP fused PfSRP14 and growth of parasite. (a) i and ii show three dimensional reconstruction of confocal Z-stack merged
images of GFP fused control trophozoite with DAPI (blue) as nuclear marker merged with DIC. (b) and (c), show the three dimensional reconstruction of confocal Z-stack
merged images of GFP fused PfSRP14 with DAPI as nuclear marker merged with DIC in control and Ivermectin (10mM) treated parasite at 24 h after treatment. (d) dose
dependent effect of ivermectin on growth of P. falciparum 3D7, MCamp and Dd2 by SYBR Green assay (e) In-vivo effect of ivermectin against P. berghei in mice
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strains Dd2, MCamp and 3D7 in a dose dependent manner
with IC50 values of 2.85, 1.92 and 1.56mM respectively
(Figure 6d). We further tested the anti-malarial activity of
ivermectin in vivo with P. berghei infected mice by adminis-
tering a 0.5 mg/kg dose of ivermectin using a modified
Thompson test (3 consecutive days of dosing). As seen in
Figure 6e, ivermectin alone suppressed day 4 parasitemias
byB40% compared to placebo-treated controls. All four mice
administered with ivermectin survived up to 23 days, while the
control mice died on day 13 (Supplementary Figure S5c).
Together these results suggest that ivermectin can be
considered for the development as an antimalarial, which
can be used in combination with other drugs.
Ivermectin is a known inhibitor of importin a/b mediated
nuclear transport.24 P. falciparum has only two important
nuclear import factors; karyopherins a and b in its genome,
while the human genome encodes numerous importins.
We next analysed the sub-cellular distribution of karyopherin
b in ivermectin treated asexual blood stages of P. falciparum
using anti-Pfkaryopherin b antibody.25 Anti-Pfkaryopherin
b recognized the parasite specific karyopherin b in untreated
parasites and staining was mainly seen in and around the
nucleus (Figure 7a, i). Intriguingly, parasites treated with
ivermectin for 21/2 hours at 100mM concentration or with 5 mM
concentration for 20 h showed restricted staining in the
cytoplasm (Figure 7a, ii and supplementary Figures S6a and b).
Faint or no staining for PfSRP9 protein was observed at 20 h
post exposure to 25 mM of ivermectin, mainly because almost
all the parasites were dead after this treatment
(Supplementary Figure S6c). Together these results suggest
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Figure 7 Effect of Ivermectin on localisation of karyopherin b, proposed mechanism of cargo import by karyopherin a- karyopherin b pathway and possible mode of action
of ivermectin. (a, i), control parasite with karyopherin b (red) and DAPI (blue) and ii, ivermectin (100mM) treated parasites after 21/2 h. (b) Karyopherin a and b form a dimer
and attach with the cargo and pass through the nuclear pore complex into nucleus where the cargo detaches itself from the karyopherins which are recycled into cytoplasm via
RanGTP. SRP subunits join SRPRNA in the nucleus and the whole conglomerate is transported back to the cytoplasm where it becomes functional. Ivermectin blocks the
parasite growth by inhibiting nucleo-cytoplasmic shuttling of SRPs essential for parasite survival either by affecting at the stage of karyopherin dimerisation or at the level of
SRP attachment with Karyopherin dimer which inturn hampers the entry of SRP to its site of RNA assembly in the nucleus. Cell death occurs because of piling up of proteins in
the cytoplasm
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that ivermectin inhibits malaria parasite development by
blocking nucleo-cytoplasmic shuttling of PfSRP components.
Discussion
Recognition of the signal sequence in the ribosome nascent-
chain (RNC) complex by SRP is the first step in protein
secretion.26 SRP couples the synthesis of membrane/
secretory proteins and their transport across the ER
membrane in eukaryotes27,28 or across the bacterial plasma
membrane8 and chloroplast thylakoid membranes.29
Considerable variations have been observed in the constitu-
ents of SRPs in different organisms.10 Among the protozoan
parasites, T. brucei and Leptomonas collosoma possess an
unusual SRP that comprises two SRP RNAs; 7SL RNA and a
tRNA like molecule and three SRP proteins; SRP19, SRP72
and SRP68, while the bacterial SRPs are of reduced
complexity consisting of a small SRP RNA and a single
protein SRP54, also referred as Ffh.10 In the present study,
in silico analysis revealed that the P. falciparum SRP is more
similar to the mammalian SRP as it consists of six poly-
peptides; PfSRP72, PfSRP68, PfSRP54, PfSRP19, PfSRP14
and PfSRP9 and a single 303 nucleotide long PfSRP RNA.
In comparison to the previous in silico studies, in the present
study two additional PfSRP polypeptides; PfSRP68 and
PfSRP72 were identified in the P. falciparum genome. It is
important to mention here that the other members of the
Alveolata to which P. falciparum belongs such as Theileria,
Eimeria as well as members of the Euglenozoa such as
Trypanosoma and Leishmania, lack one or two of the six SRP
polypeptides. For example SRP9/14 has not been identified in
L.major, T. cruzi, Thelileria annulata, andGiardia lamblia.10,11
A number of structural and protein–RNA interactions studies
for E. coli and mammalian SRPs have provided insights into
the assembly of SRPs and also delineated the interaction
motifs (residues) between SRP54 and SRP RNA.30–32
However, our understanding of SRPs in lower eukaryotes
has been limited. Here we identified and report some of the
essential features of P. falciparum SRP. The results demon-
strate that all the components of mammalian SRP are
conserved in the P. falciparum genome. We further show
that Plasmodium SRP assembly process appears to be
similar to that of human SRP assembly. The binding of
PfSRP19 to PfSRP RNA most likely induces conformational
changes in PfSRP RNA that subsequently binds to other
components; such as PfSRP54, PfSRP14 and PfSRP9.
Additionally, we demonstrate that during PfSRP assembly
various PfSRP proteins also interact with each other,
presumably to stabilize the PfSRP.
The sub-cellular localization studies performed for PfSRP
proteins showed a clear nucleolar as well as cytoplasmic
distribution for PfSRP9, PfSRP14 and PfSRP19 polypeptides
at asexual blood stages by anti-PfSRPs antibodies and by
GFP fluorescence analysis in transgenic lines. This was
further confirmed by co-localization experiments with the
nucleolar and ER markers. Importantly, PfSRP54 also
showed nucleoplasmic distribution, although its level in the
nucleus was low in comparison to other PfSRP polypeptides.
Significantly, we could also observe PfSRP54 co-localization
with PfNOP1, a nucleolar marker especially in earlier stages
of development. It has been proposed that nucleolus is the site
of assembly and/or interaction between the families of
mammalian ribonucleoproteins involved in protein synthesis,
in addition to ribosomes themselves.33–35 However, in
mammalian cells, SRP54 does not seem to have a nucleolar
phase.12 Based on these findings, it has been suggested that
in mammalian cells, SRP is partially assembled in the nucleus
and it is piggybacked with ribosomal units for export from the
nucleus.36 In the cytoplasm, the partially assembled SRP is
joined by SRP54 that recognizes the nascent signal
sequence.33 Based on the data for the localization of PfSRP
proteins and mammalian SRP proteins, it seems more likely
that in the case of PfSRP, complete assembly may occur in
nucleus and this assembled complex is then transported to
cytoplasm to perform ER targeting.
The movement of proteins between the nucleus and
cytoplasm is an essential process and has been shown to
be critical for the disease states such as parasitic diseases,
viral diseases and oncogenesis. Although seven importin as
and 420 importin bs have been described in human along
with a wide range of NLS/NES sequences that are required for
this transport, functional role(s) of each transporter in specific
protein shuttling across nuclear membrane is not still under-
stood.23 Currently, the exportin/CRM1 inhibitor, Leptomycin B
and importin a/b inhibitor, ivermectin are the only accepted
inhibitors being used to inhibit nuclear transport in mammalian
cells. We used these inhibitors along with aflatoxin B1 to study
their effect on PfSRP polypeptides and their nucleo-cytoplasmic
shuttling. Importantly, neither Leptomycin B, nor aflatoxin B1
affected the localization and distribution of PfSRP-GFP
polypeptides and these treated parasites grew normally in
in vitro culture. In comparison, ivermectin, a specific inhibitor
of importin a/b blocked the nucleo-cytoplasmic shuttling of
SRP polypeptides; PfSRP9-GFP and PfSRP14-GFP chimera
proteins were mainly seen in the parasite cytoplasm in the
ivermectin treated parasites. Ivermectin showed a potent
inhibition in the growth of P. falciparum 3D7 as well as other
drug resistant strains, Mcamp and DD2. Ivermectin treated
P. falciparum parasites also showed a dramatic change in the
level as well as the distribution of karyophorin b. Limited in vivo
studies in a P. berghei mice model further demonstrated the
antimalarial effect of ivermectin.
Ivermectin has been shown to inhibit replication of HIV-1
and Dengue virus by blocking the shuttling of nuclear proteins
mediated by importin a/b. In nematodes, ivermectin is known
to bind and activate chloride ion channels,37 a phenomenon
which has been shown to be responsible for its anti-parasitic
effect. Ivermectin also causes cell death in leukemia cells by
inducing the chloride dependent membrane hyperpolarization.
Based on these studies, it has been proposed that ivermectin
affects the shuttling of importin a/b by inducing the chloride
dependent polarization of parasite nuclear membrane that in
turn inhibits the nuclear import of SRP polypeptides. Since
karyopherin a/b are the only known importins present in
P. falciparum, it is likely that ivermectin treatment is arresting
parasite growth by blocking the shuttling of SRP polypeptides
and some other nuclear proteins (Figure 7b). Ivermectin has
recently been shown to inhibit the sporogony of P. falciparum
in Anopheles gambiae.38 Although a detailed in vivo analysis
will be required for the use of ivermectin as an antimalarial
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agent, however given the prior use of ivermectin and its safety
record in humans and animals, it can be considered in
combination therapy with other antimalarials. In conclusion,
the results presented here provide insights into the malaria
parasite PfSRP and show that ivermectin an anti-parasitic has
the potential to treat multi-drug resistant malaria.
Materials and Methods
Generation of PfSRP-GFP lines. To generate P. falciparum’s SRPs-GFP
lines, genes corresponding to PfSRP54, -19, -14, -9 were PCR amplified and
cloned into pSSPF2. The plasmids were transfected into P. falciparum 3D7 line
and transfected cells were selected as described in detail in SI text.
Analysis of protein–RNA and protein–protein interactions.
In-vitro interactions between PfSRPs and PfSRP RNA were performed using
well established RNA binding assay as described in SI text. Protein–protein
interactions between four PfSRP components were performed using bacterial two
hybrid system and ELISA as described in SI text.
Effect of inhibitors on PfSRP-GFP transgenic lines. P. falciparum
culture was synchronised by two consecutive sorbitol treatments at an interval of
four hours. The parasite culture was incubated with different concentrations of
leptomycinB, aflatoxin B1 and ivermectin as described in SI text.
Growth inhibition assay on P. falciparum 3D7, Dd2 and mCAMP
strains. Parasite culture with an initial parasitemia of 0.8% was treated with
different doses of leptomycin B, aflatoxin B1 and ivermectin in 96 well plate and
new ring formation was monitored as described in SI text.
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